Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

510P - Long-term outcomes of COVID-19 infection in patients with solid tumors before vaccination

Date

10 Sep 2022

Session

Poster session 13

Topics

COVID-19 and Cancer

Tumour Site

Presenters

Ozan Yazici

Citation

Annals of Oncology (2022) 33 (suppl_7): S227-S232. 10.1016/annonc/annonc1052

Authors

O. Yazici1, O. Ünsal1, Ö.F. Özkan2, N. Ozdemir1, G. Tahtaci1, A. Uner1, N. Günel1, A. Özet1

Author affiliations

  • 1 Medical Oncology Department, Gazi University - Faculty of Medicine, 06560 - Ankara/TR
  • 2 Internal Medicine, Gazi University - Faculty of Medicine, 06560 - Ankara/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 510P

Background

During the pandemic, there have been significant developments in the implementation of preventive measures, including follow up of COVID-19 infection and contact, increased testing capacity, and vaccination. On the other hand, the fluctuating course continues due to the COVID-19 variants. Cancer patients are among the groups most affected by the pandemic. In this study, it was aimed to investigate the long-term effects of COVID-19 infection in cancer patients before vaccination.

Methods

All patients who were followed up with a diagnosis of solid cancer and had SARS-CoV-2 infection (positive nasopharyngeal swab) between May 2020 and December 2020 (pre-vaccine period) were included in the study.

Results

742 solid tumor patients were included in the study. Fifty-one point one percent of the patients were male. The median age was 61 (18-94) years and the median follow-up time from cancer diagnosis was 23 months (1-331). Distribution of the most frequent diagnoses by cancer subtypes; 25.7% were lung cancer, 24.9% gastrointestinal system cancer and 19.4% breast cancer. Fifteen point nine percent of the patients had one comorbidity and 13.9% had at least 2 comorbidities. In the last 3 months before COVID-19 infection, 51.6% of the patients were receiving anticancer treatment. The median follow-up period of the patients from the diagnosis of COVID-19 infection was 16 (1-24) months. During the follow-up, 35.7% of the patients died. On the other hand, 28.3% of the patients died from COVID-19 and its complications. When mortality due to COVID-19 infection was examined, it was seen that patients diagnosed with lung cancer (19.9%) were the most common cancer subgroups (19.9%) (p:0.01). When COVID-19-related mortality was examined, it was found that patients who received targeted therapy were more related with mortality (25.7%) (p:0.01).

Conclusions

Considering the mortality rates, it is clear that patients with solid tumors are more affected by the COVID-19 pandemic than the normal population. It is important to evaluate the effectiveness of preventive measures and planning future strategies. The pandemic is likely to have long-term consequences as well as short-term consequences.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

O. Yazici.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.